<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006911</url>
  </required_header>
  <id_info>
    <org_study_id>PBOPC02</org_study_id>
    <nct_id>NCT05006911</nct_id>
  </id_info>
  <brief_title>Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms</brief_title>
  <acronym>PBO</acronym>
  <official_title>Pilocarpine, Brimonidine, Oxymetazoline Ophthalmic Compound Safety and Efficacy in Patients With Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optall Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optall Vision</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac&#xD;
      (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients&#xD;
      one hour after instillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the safety and efficacy of a novel pharmacological compound of Pilocarpine,&#xD;
      Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) to improve uncorrected near&#xD;
      vision in healthy presbyopic patients one hour after binocular instillation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>To determine safety and efficacy of a Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac compound to improve near uncorrected vision in healthy presbyopic patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Jaeger near uncorrected visual acuity improvement</measure>
    <time_frame>1 hour</time_frame>
    <description>Measure uncorrected near vision change after binocular instillation of PBOHB compound</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>PBOHB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac to evaluate safety and efficacy to improve uncorrected near vision in healthy presbyopic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound</intervention_name>
    <description>To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.</description>
    <arm_group_label>PBOHB</arm_group_label>
    <other_name>PBOHB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Presbyopic&#xD;
&#xD;
          -  40 - 60 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetics&#xD;
&#xD;
          -  Previous eye surgery&#xD;
&#xD;
          -  Previous eye disease&#xD;
&#xD;
          -  &gt; 0.50 myopia&#xD;
&#xD;
          -  &gt; 1.5 hyperopia or astigmatism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesar Alejandro S Galeana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optall Vision</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cesar Alejandro S Galeana, MD</last_name>
    <phone>5541851511</phone>
    <email>optallvision@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosario Perez</last_name>
    <phone>559199042</phone>
    <email>optallvision@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Optall Vision</name>
      <address>
        <city>Mexico City</city>
        <zip>01090</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Alejandro S Galeana, MD</last_name>
      <phone>5541851511</phone>
      <email>optallvision@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Optall Vision</investigator_affiliation>
    <investigator_full_name>Cesar Alejandro Sanchez Galeana</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

